Market Overview

Analyst: Why Humana And Walmart Could Make Sense Together

Share:
Analyst: Why Humana And Walmart Could Make Sense Together

Retail giant Walmart Inc (NYSE: WMT) is reportedly in early discussions with Humana Inc (NYSE: HUM) that include the possibility of an outright acquisition, The Wall Street Journal reported.

The Analyst

Stifel's Mark Astrachan maintains a Hold rating on Walmart's stock with an unchanged $99 price target.

The Thesis

The strategic merits of a potential deal include the following, Astrachan said:

  • The addition of new customer data could be additive to store traffic and help Walmart learn more about the health care industry. Cost savings, particularly for health care products and services.
  • The ability for Walmart to sustain heightened investment levels.
  • A "proactive response" to Amazon's potential entry into the health care services.

A Humana deal could be approximately 3-to-4-percent accretive to Walmart's earnings per share, the analyst said. (See Astrachan's track record here.) 

"That said, a potential transaction would also meaningfully increase the complexity of Walmart's business, including adding a heavily regulated entity that derives 79 percent of premium and services revenue from contracts with the U.S. government," Astrachan said. 

Walmart and Humana have an existing relationship through their co-branded prescription drug offering, the analyst said. If an acquisition isn't realized, the two companies can still expand their relationship — in a manner similar to CVS' strategy of expanding in-store medical clinics for basic services — which in turn will drive incremental traffic into Walmart stores, according to Stifel. 

Price Action

Shares of Humana were trading higher by 6.2 percent at the time of publication Monday. Amazon shares were down 3.7 percent. 

Related Links:

Leerink's Takeaways From CNBC's 'Healthy Returns' Conference

Cramer: Here's Why Centene Is A Buy Amid Amazon's Health Care Push

Latest Ratings for HUM

DateFirmActionFromTo
Jan 2020MaintainsOutperform
Jan 2020MaintainsOverweight
Jan 2020MaintainsBuy

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Analyst Color M&A News Health Care Price Target Reiteration Top Stories Analyst Ratings Best of Benzinga

 

Related Articles (HUM + WMT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
VALB of A SecuritiesMaintains5.0
HALB of A SecuritiesMaintains28.0
PPLB of A SecuritiesMaintains35.0
PNWB of A SecuritiesMaintains97.0
IRBTB of A SecuritiesMaintains56.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com